Immutep Crecimiento futuro

Future controles de criterios 2/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Immutep de 1.1% y 52.5% por año respectivamente. Se prevé que el BPA crezca en un 7.2% al año. Se espera que la rentabilidad financiera sea de -75.1% en 3 años.

Información clave

1.1%

Tasa de crecimiento de los beneficios

7.2%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	26.8%
Tasa de crecimiento de los ingresos	52.5%
Rentabilidad financiera futura	-75.1%
Cobertura de analistas	Low
Última actualización	16 Dec 2024

Actualizaciones recientes sobre el crecimiento futuro

No hay actualizaciones

Recent updates

Immutep stock climbs on FDA fast track status for eftilagimod to treat lung cancer subtype

Oct 04

Immutep secures €1.8M cash in French government's research tax credit

Sep 23

Immutep gets Japanese patent for immunotherapy eftilagimod alpha combo

Aug 30

Immutep gets Japanese patent related to autoimmune disease drug candidate IMP761

Jul 06

Immutep: Australian Immune-Focused Company, Pureplay LAG3 Player

Jun 12

Immutep - LAG3 Checkpoint Receives First FDA Approval; Positive For This LAG3 Pure Play

Mar 21

Immutep expands the evaluation of efti into a triple combination therapy, shares down 12%

Jun 21

Immutep reveals anti-LAG-3 research program

Jun 08

Immutep jumps 9% on Chinese patent for efti in chemo-immunotherapy combination

May 26

Immutep completes recruitment in efti mid-stage study in head & neck cancer

Jan 07

Previsiones de crecimiento de beneficios e ingresos

NasdaqGM:IMMP - Estimaciones futuras de los analistas y datos financieros pasados (AUD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
6/30/2027	42	-39	-76	-39	3
6/30/2026	5	-70	-76	-76	3
6/30/2025	5	-65	-82	-68	3
6/30/2024	4	-43	-36	-35	N/A
3/31/2024	4	-42	-39	-38	N/A
12/31/2023	4	-41	-42	-42	N/A
9/30/2023	4	-40	-39	-39	N/A
6/30/2023	4	-40	-35	-35	N/A
3/31/2023	4	-38	-33	-33	N/A
12/31/2022	4	-37	-30	-30	N/A
9/30/2022	5	-34	-30	-30	N/A
6/30/2022	5	-32	-30	-30	N/A
3/31/2022	4	-29	-25	-25	N/A
12/31/2021	4	-26	-20	-20	N/A
9/30/2021	4	-28	-19	-19	N/A
6/30/2021	4	-30	-18	-18	N/A
3/31/2021	5	-29	-16	-16	N/A
12/31/2020	6	-27	-15	-15	N/A
9/30/2020	10	-20	-13	-13	N/A
6/30/2020	14	-13	-11	-11	N/A
3/31/2020	13	-15	-13	-13	N/A
12/31/2019	13	-16	-14	-14	N/A
9/30/2019	9	-17	-15	-15	N/A
6/30/2019	6	-18	-15	-15	N/A
3/31/2019	5	-18	-13	-13	N/A
12/31/2018	5	-17	-10	-10	N/A
9/30/2018	6	-15	-9	-9	N/A
6/30/2018	7	-13	-8	-8	N/A
3/31/2018	6	-12	N/A	-8	N/A
12/31/2017	7	-10	N/A	-8	N/A
9/30/2017	5	-9	N/A	-8	N/A
6/30/2017	4	-9	N/A	-9	N/A
3/31/2017	3	-10	N/A	-8	N/A
12/31/2016	2	-10	N/A	-9	N/A
9/30/2016	2	-36	N/A	-10	N/A
6/30/2016	2	-62	N/A	-11	N/A
3/31/2016	2	-71	N/A	-10	N/A
12/31/2015	1	-82	N/A	-8	N/A
9/30/2015	1	-57	N/A	-8	N/A
6/30/2015	1	-32	N/A	-8	N/A
3/31/2015	1	-23	N/A	-10	N/A
12/31/2014	1	-14	N/A	-13	N/A
9/30/2014	2	-14	N/A	-13	N/A
6/30/2014	2	-13	N/A	-14	N/A
3/31/2014	2	-13	N/A	-14	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que IMMP siga sin ser rentable en los próximos 3 años.

Beneficios vs. Mercado: Se prevé que IMMP siga sin ser rentable en los próximos 3 años.

Beneficios de alto crecimiento: Se prevé que IMMP siga sin ser rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (52.5% al año) de IMMP crezcan más rápidamente que los del mercado US (9% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos (52.5% al año) de IMMP crezcan más rápidamente que un 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: IMMP se prevé que no sea rentable en 3 años.

Descubre empresas en crecimiento

Análisis de la empresa y estado de los datos financieros

Datos	Última actualización (huso horario UTC)
Análisis de la empresa	2025/01/05 09:01
Precio de las acciones al final del día	2025/01/03 00:00
Beneficios	2024/06/30
Ingresos anuales	2024/06/30

Fuentes de datos

Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.

Paquete	Datos	Marco temporal	Ejemplo Fuente EE.UU. ^*
Finanzas de la empresa	10 años	Cuenta de resultados Estado de tesorería Balance	Formulario SEC 10-K Formulario SEC 10-Q
Estimaciones del consenso de analistas	+3 años	Previsiones financieras Objetivos de precios de los analistas	Informes de análisis Blue Matrix
Precios de mercado	30 años	Precios de las acciones Dividendos, escisiones y acciones	Datos de mercado ICE Formulario S-1 de la SEC
Propiedad	10 años	Accionistas principales Información privilegiada	Formulario SEC 4 Formulario SEC 13D
Gestión	10 años	Equipo directivo Consejo de Administración	Formulario SEC 10-K Formulario SEC DEF 14A
Principales avances	10 años	Anuncios de empresas	Formulario SEC 8-K

^* ejemplo para los valores estadounidenses, para los no estadounidenses se utilizan formularios y fuentes normativas equivalentes.

A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Obtenga más información aquí.

Modelo de análisis y copo de nieve

Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.

Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.

Métricas industriales y sectoriales

Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en .

Fuentes analistas

Immutep Limited está cubierta por 17 analistas. 4 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.

Analista	Institución
Joel Beatty	Baird
Thomas Wakim	Bell Potter
Tara Speranza	Bell Potter

Immutep Crecimiento futuro

Future controles de criterios 2/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Immutep Announces Initial Safety Data from First-in-Human Phase I Trial Evaluating IMP761

Immutep Limited and Monash University Announce First Publication Detailing How Human LAG-3 Binds to MHC Class II

Immutep Limited Reports Promising New Data in Head and Neck Cancer At ESMO Immuno-Oncology 2024

Immutep Limited Announces Initiation of TACTI-004 Phase III Trial in First Line Non-Small Cell Lung Cancer

Immutep: Potential Of Efti As New Standard Of Care For NSCLC Patients

Immutep Limited, Annual General Meeting, Nov 22, 2024

Immutep Limited Announces Resignation of Anne Anderson as Independent Non-Executive Director

Immutep Completes Patient Enrolment in Randomised Phase II of AIPAC-003 Trial in Metastatic Breast Cancer

Immutep Limited Announces New Data from Eftisarc-Neo Phase II Evaluating Novel Triple Combination Including Immutep's Efti in Soft Tissue Sarcoma

Immutep Limited Announces Positive Efficacy and Safety Results from the TACTI-003 Phase IIb Trial Evaluating Eftilagimod Alpha

Immutep Limited Announces Late-Breaking Abstract in Head & Neck Cancer Selected for Oral Presentation at ESMO Congress

Immutep Announces First Participant Dosed in Phase I Study of Imp761, A First in Class Agonist Lag-3 Antibody

Immutep Announces Successful Meeting with FDA on Phase III Design in Non-Small Cell Lung Cancer

Immutep Limited Receives Regulatory Clearance for Phase I Study of First-In-Class Lag-3 Agonist Antibody Designed to Treat Autoimmune Diseases

Immutep: Positive Efti Treatment Data Leads To Late-Stage Programs

Immutep Reports Positive Results in First Line Head and Neck Squamous Cell Carcinoma Patients with Negative Pd-L1 Expression

Immutep Limited Announces Clinical Collaboration with Msd to Evaluate Efti in Combination with Keytruda®? (Pembrolizumab) in Pivotal Phase Iii Trial

Immutep Limited Presents Data from Safety Lead-In Phase of AIPAC-003 at ESMO Breast 2024

Immutep Limited Reports Positive Initial Clinical Data Reported from Efti Combined with Radiotherapy and Checkpoint Inhibitor from Phase II Trial in Soft Tissue Sarcoma

Immutep: Realizing The Expected Catalysts, With More To Come

Immutep Limited Announces Positive Preliminary Topline Results from TACTI-003 Cohort B

Immutep Limited Appoints Leading Research Institute to Conduct First-In-Human Phase I Study of IMP761

Immutep Limited Receives Positive Feedback from the Spanish Medicines Agency for Upcoming Tacti-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer

Immutep Limited Announces First Clinical Data from 90Mg Dosing of Efti

Immutep Limited Announces First Patient Dosed in Trial Evaluating Efti and the Anti-PD-L1 Therapy BAVENCIO in Metastatic Urothelial Cancer

Immutep Limited Receives Constructive Regulatory Feedback on TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer

Immutep Limited Completes Enrollment in TACTI-003 Phase IIb Trial of Efti and KEYTRUDA(R) in First Line Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma

Immutep Announces New Biomarker Data from Tacti-002 Phase II in First Line Non-Small Cell Lung Cancer

Immutep Limited Reports Promising Clinical Data from Insight-003 Trial at ESMO Congress 2023

Immutep Limited Announces Excellent New Clinical Data from the TACTI-002 / KEYNOTE-798 Phase II Trial Evaluating Eftilagimod Alpha

Immutep Limited Announces Commercial Manufacturing of Eftilagimod Alpha at 2000L Scale Granted Authorization for Clinical Trial Use

Immutep Limited, Annual General Meeting, Oct 24, 2023

Immutep Limited Receives Positive Scientific Advice from Committee for Medicinal Products for Human Use of European Medicines Agency for Continued Development of Eftilagimod Alpha

Immutep Limited Announces First Patient Dosed in Chemotherapy-Free Triple Combination Phase II Trial Targeting Soft Tissue Sarcoma

Immutep Limited Doses First Patient in AIPAC-003 Phase II/III Trial for Metastatic Breast Cancer

Immutep Limited Announces Efti in Combination with Pembrolizumab Achieves Excellent Initial Overall Survival Benefit in 1st Line Non-Small Cell Lung Cancer

Immutep Limited Receives Positive Feedback from FDA on Late-Stage Clinical Development of Eftilagimod Alpha in Non-Small Cell Lung Cancer

Immutep Reaches Enrolment Target for INSIGHT-003 Trial in 1st Line NSCLC

Immutep Limited Announces Update on INSIGHT-003 Trial in NSCLC

Immutep Limited Enrolls and Randomised over 50% of the Planned 154 Patients in the Tacti-003 Phase IIB Trial

Immutep Limited Announces the Results of Positive Follow-Up Type C Meeting with the US Food and Drug Administration

Immutep Limited Announces the Successful Scale-Up of the Manufacturing of its Lead Product Candidate Eftilagimod Alpha

Immutep Limited Announces GMP Manufacturing Process Developed for IMP761, a First-in-Class LAG-3 Agonist for Autoimmune Disease

Immutep Limited Announces Compelling Clinical Results from Phase II Trial Utilizing its First-in-Class Soluble LAG-3 Protein, Eftilagimod Alpha, in 1st Line NSCLC at SITC 2022 Annual Meeting

Immutep Limited Announces Independent Data Monitoring Committee Positive Recommendation to Continue TACTI-003 Trial as Planned

Immutep Limited Announces the United States Food and Drug Administration (Fda) Has Granted Fast Track Designation to Eftilagimod Alpha

Immutep stock climbs on FDA fast track status for eftilagimod to treat lung cancer subtype

Immutep secures €1.8M cash in French government's research tax credit

Immutep Limited, Annual General Meeting, Nov 23, 2022

Immutep Clinical Development Update for its LAG-3 Antigen Presenting Cell Activator Candidate Eftilagimod Alpha

Immutep Clinical Development Update for its LAG-3 Antigen Presenting Cell Activator Candidate Eftilagimod Alpha

Immutep Appoints Frederic Triebel as Executive Director

Immutep Limited Announces Investigator-Initiated Phase Ii Trial Evaluating LAG-3 Candidate Eftilagimod Alpha (Efti) in Soft Tissue Sarcoma

Immutep Limited Announces Investigator-Initiated Phase Ii Trial Evaluating LAG-3 Candidate Eftilagimod Alpha (Efti) in Soft Tissue Sarcoma

Immutep Limited Grants Japanese Patent for Eftilagimod Alpha, a Soluble Lag-3 Protein, in Combination with a PD-1 Pathway Inhibitor

Immutep gets Japanese patent for immunotherapy eftilagimod alpha combo

Immutep Limited Reports New Positive Interim Data from its Phase II Study of LAG-3 Candidate, Eftilagimod Alpha, in 2nd Line PD-X Refractory NSCLC

Immutep Limited Provides an Update on the Ongoing Development of Its Product Candidates, eftilagimod alpha and IMP76 for the Quarter Ended 30 June 2022

Immutep gets Japanese patent related to autoimmune disease drug candidate IMP761

Immutep: Australian Immune-Focused Company, Pureplay LAG3 Player

Immutep Limited Reports Positive Overall Response Rate in Its Phase II Clinical Trial in 1st line NSCLC for PD-L1 All-Comers

Immutep Limited Announces Executive Changes

Immutep Limited Presents New and Significant Data from the AIPAC Study

Immutep Limited Provides Update on the Ongoing Development of Its Product Candidates, Eftilagimod Alpha and IMP761 for the Quarter Ended 31 March 2022

Immutep’S Efti in Combination with Msd’S Pembrolizumab Shows Encouraging Antitumor Activity in Difficult to Treat 2Nd Line Metastatic Lung Cancer Patients

Immutep Limited Announces New Interim Data in 2nd Line Metastatic NSCLC from Its Phase II TACTI-002 Trial

Immutep - LAG3 Checkpoint Receives First FDA Approval; Positive For This LAG3 Pure Play

Immutep Limited Appoints Lucy Turnbull as Non-Executive Director

Immutep Limited to Present New Data from the Phase II TACTI-002 Study of Efti at ESMO’s European Lung Cancer Congress 2022

Immutep Limited to Present New Data from the Phase II TACTI-002 Study of Efti At ESMO's European Lung Cancer Congress 2022

Immutep Limited Announces Demise of Grant Chamberlain, Non-Executive Director

Immutep Limited Provides an Update on the Ongoing Development of Its Product Candidates, Eftilagimod Alpha

Immutep Limited Reports Good Safety from First Five Patients in the INSIGHT-003 study

Immutep to Present Final Overall Survival Data from Phase IIb AIPAC as a Late Breaking Poster Presentation At SITC 2021

Immutep Limited Provides an Update on the Ongoing Development of Its Product Candidates